NCT01500538 - A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2014

Conditions

Follicular LymphomaMarginal Zone LymphomaMantle Cell Lymphoma

Interventions

DRUG

Eltrombopag and Vorinostat

4 week mono-therapy eltrombopag, commencing at 50mg/day, increasing to 200mg. Daily intake of 400mg vorinostat for minimum of 6 cycles, each cycle of 4 weeks, possibly in combination with daily intake eltrombopag commencing at 50mg/day at a maximum dose of 200md/day (150mg/day for subjects of East-Asian ancestry)

Trial Locations (1)

3002

Peter MacCallum Cancer Centre, Melbourne